List Trials for Recurrent Pancreatic Cancer

Pancreatic Cancer


MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Closed;   Study ID: NCT01988896

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone for Patients With Resected Pancreatic Cancer (20140859)
A Phase 3, Multicenter, Open-label, Randomized Study of nabĀ®-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

Investigator: Gabriela Chiorean;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01964430

Ruxolitinib for Advanced or Metastatic Pancreatic Cancer (20141052)
A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)

Investigator: Gabriela Chiorean;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT02117479

Combination Chemotherapy w w/o PEGPH20 for Pancreatic Cancer (SWOG 1313)
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma

Investigator: Gabriela Chiorean, MD;   Conditions: Pancreatic Cancer;    Status: Pending;   Study ID: NCT01959139

90Y-Clivatuzumab Tetraxetan + Low-Dose Gemcitabine for Metastatic Pancreatic Cancer (20151371)
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)

Investigator: Andrew Coveler, MD;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01956812